MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $762.73M
• Dividend Yield: N/A
• Average Volume (3M): 881.06K
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.65
• Revenue Growth: 14.77%
• EPS Growth: -58.90%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 148,102,160
• 10 Day Avg. Volume: 1,157,657
• 30 Day Avg. Volume: 881,056
• PEG Ratio: -0.84
• Price to Book (P/B): 7.32
• Price to Sales (P/S): 4.05
• P/FCF Ratio: 21.92
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 1.62
• Enterprise Value/Gross Profit: 1.98
• Enterprise Value/Ebitda: 9.10
• 1Y Price Target: $10.00
• Price Target Upside: 94.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $5.50 ▲(7.00% Upside)

The score is driven primarily by solid financial performance (strong cash flow and improved balance sheet) and a strong earnings update with raised guidance, partially offset by weak technical momentum (below major moving averages with negative MACD and low RSI/Stoch) and only moderate valuation support (P/E ~23 with no dividend yield provided).

Positive Factors

Cash generation & liquidity

Strong free cash generation and a sizable net cash balance provide durable financial flexibility. This enables funding of clinical programs, commercial expansion, targeted M&A, and buffers versus policy shocks, reducing reliance on external financing and supporting multi-quarter strategic execution.

Balance sheet strength

Extremely low leverage and a high equity ratio materially lower solvency risk and give the company capacity to invest in R&D and scale commercialization. A robust ROE indicates efficient capital deployment, supporting long-term resilience through industry cycles or adverse events.

Revenue growth & franchise diversification

Sustained double-digit top-line growth across both Wound and Surgical franchises demonstrates product-market fit and diversified demand drivers. Broad-based expansion supports scale economics, clinical evidence gathering, and potential market share gains that can underpin durable revenue momentum.

Negative Factors

Margin compression

Declining net and operating margins, despite revenue growth, point to structural cost or pricing pressures—potentially from higher operating expenses, legal costs, or reimbursement dynamics. Persistent margin erosion would weaken cash conversion and constrain reinvestment over multiple quarters.

Medicare reimbursement uncertainty

Structural reimbursement reform could change payment rates or coding for placental-derived products, altering realized pricing and hospital adoption economics. As a payor-driven shift, this represents a multi-quarter revenue and margin risk requiring commercial and coding adaptation to preserve long-term profitability.

Ongoing legal & regulatory costs

Persistent litigation and regulatory expenses raise recurring G&A, create contingent liabilities, and divert management focus. Over time, these costs can erode free cash flow available for growth initiatives, hinder partnerships, and introduce execution risk that may depress long-run returns.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its allograft tissue products. The company sells these products to hospitals, outpatient surgical centers, and other healthcare providers. Revenue streams are largely derived from the distribution of its advanced wound care and orthopedic solutions, with a significant emphasis on the management of chronic wounds such as diabetic foot ulcers and venous leg ulcers. MiMedx has established partnerships with various healthcare organizations and distributors, which enhance its market reach and customer base. The company's financial performance is also influenced by trends in healthcare spending, the adoption of regenerative medicine, and the regulatory environment surrounding tissue-based therapies.

MiMedx Group Financial Statement Overview

Summary

Solid fundamentals supported by strong cash generation (cash flow score 80) and improved leverage/equity position (balance sheet score 70). Income statement strength is tempered by declining net/EBIT/EBITDA margins despite revenue growth (income statement score 75).

Income Statement

MiMedx Group has shown consistent revenue growth, with a notable 8.16% increase in the TTM period. The gross profit margin remains strong at 81.99%, indicating efficient cost management. However, the net profit margin has decreased from 12.16% in 2024 to 10.38% in the TTM, suggesting some pressure on profitability. The EBIT and EBITDA margins have also declined, reflecting potential operational challenges.

Balance Sheet

The company's debt-to-equity ratio has improved significantly, dropping to 0.0057 in the TTM, indicating a strong equity position and reduced leverage. Return on equity is robust at 19.18%, although it has decreased from previous years. The equity ratio stands at 74.86%, showcasing a solid capital structure. However, past periods of negative equity and high leverage pose a risk if financial conditions change.

Cash Flow

MiMedx Group's cash flow performance is strong, with a 10.58% growth in free cash flow in the TTM. The operating cash flow to net income ratio is healthy at 1.18, indicating efficient cash generation relative to profits. The free cash flow to net income ratio is stable at 1.0, suggesting that the company effectively converts its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	393.44M	348.88M	321.48M	267.84M	242.02M	248.23M
Gross Profit	322.57M	288.81M	266.84M	219.53M	202.39M	208.90M
EBITDA	70.05M	65.35M	40.54M	-10.68M	-1.89M	-37.52M
Net Income	40.83M	42.42M	67.44M	-30.20M	-12.30M	-49.28M
Balance Sheet
Total Assets	318.99M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	142.08M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	18.21M	24.84M	48.10M	52.47M	53.29M	51.83M
Total Liabilities	80.04M	70.81M	96.33M	96.92M	95.35M	110.61M
Stockholders Equity	238.95M	193.11M	142.72M	74.51M	92.58M	91.42M
Cash Flow
Free Cash Flow	63.53M	64.52M	24.79M	-19.41M	-5.20M	-34.49M
Operating Cash Flow	67.83M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-9.32M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-5.23M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 5.14 is below the 20-day moving average (MA) of 5.79, below the 50-day MA of 6.47, and below the 200-day MA of 6.75, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 22.44 is Positive, neither overbought nor oversold. The STOCH value of 12.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	70 Outperform	$762.73M	18.83	19.44%	―	14.77%	-58.90%
PHAR	66 Neutral	$1.43B	1,436.81	0.44%	―	26.54%	―
MAZE	65 Neutral	$2.09B	-19.96	-36.13%	―	―	―
ORIC	54 Neutral	$1.07B	-6.22	-39.73%	―	―	4.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATAI	48 Neutral	$1.41B	-4.77	―	―	―	―

MiMedx Group Corporate Events

MiMedx Group Updates Strategy in Wound Care Markets

On January 12, 2026, MiMedx Group updated its investor presentation, highlighting its strategy to drive growth in the sizeable wound care and surgical markets through innovation in placental-derived products, expanded clinical evidence, and disciplined capital allocation. The materials emphasize ongoing and planned clinical studies across multiple surgical specialties, the significant unmet medical and economic burden of chronic wounds and postoperative complications such as colorectal anastomotic leaks, and the company’s focus on leveraging its product portfolio and strong balance sheet to support continued revenue growth, profitability, and potential expansion via M&A, with implications for reinforcing its competitive position and value creation objectives for stakeholders.

The most recent analyst rating on (MDXG) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.